



***Mycobacterium tuberculosis* Infection: Policy Gaps and Research Breakthroughs**

Guest Editors:

Dr. Anca Vasiliu

Department of Pediatrics, Baylor
College of Medicine, Houston, TX,
USA

Dr. Anna Maria Mandalakas

Department of Pediatrics, Baylor
College of Medicine, Houston, TX,
USA

Dr. Maryline Bonnet

Institut de Recherche pour le
Développement, TransVIHMI,
University of Montpellier,
Montpellier, France

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Mycobacterium tuberculosis (TB) infection is defined as a state of persistent immune response to stimulation by *Mycobacterium tuberculosis* antigens with no evidence of clinically manifest active TB. This Special Issue presents state-of-the-art knowledge on TB infection and highlights existing progress toward better understanding TB transmission and prevention, TB infection policies and their cost-effectiveness, innovative TB screening technologies and strategies, and best practices for TB infection control and prevention. This collection of articles aims at advancing our current understanding of TB infection. Recent paradigm shifts in TB transmission and the influence COVID-19 has on TB infection will be explored. A chapter will be dedicated to advances in TB vaccination and expected timelines for broad use. There will be specific chapters on vulnerable populations such as children, adolescents, pregnant women, and PLHIV. Integration and adaptation of TB infection strategies will be covered, with a special focus on new technologies designed to improve adherence to preventive therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)